Treatment of multiple myeloma has substantially changed over the past decade with the
introduction of several classes of new effective drugs that have greatly improved the rates …

New approaches to stratify multiple myeloma patients based on prognosis and therapeutic
decision-making, or prediction, are needed since patients are currently managed in a similar …

PURPOSE Assessing measurable residual disease (MRD) has become standard with many
tumors, but the clinical meaning of MRD in multiple myeloma (MM) remains uncertain …

More than 30 years after its introduction, autologous stem cell transplantation (ASCT)
remains the standard of care for young patients with newly diagnosed multiple myeloma. Not …

Purpose To perform a critical analysis on the impact of depth of response in newly
diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 …

Background Data are lacking on whether lenalidomide maintenance therapy prolongs the
time to disease progression after autologous hematopoietic stem-cell transplantation in …

Multiple myeloma is characterized by underlying clinical and biological heterogeneity, which
translates to variable response to treatment and outcome. With the recent increase in …

We assessed the prognostic value of minimal residual disease (MRD) detection in multiple
myeloma (MM) patients using a sequencing-based platform in bone marrow samples from …

Assessment of minimal residual disease (MRD) is becoming standard diagnostic care for
potentially curable neoplasms such as acute lymphoblastic leukemia. In multiple myeloma …

In the past decade, one of the major advances in the management of patients with
symptomatic newly diagnosed multiple myeloma has been the introduction of novel agents …